|Product||Target||Indication||Lead OpPreclinPhase 1Phase 2Phase 3|
type 1 receptor
|Acute Heart Failure||intravenous|
|Moderate to Severe Pain||oral|
|Parkinson's disease, Pain, Depression||oral|
TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. Trevena is developing TRV130 for the treatment of moderate to severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute postoperative pain.
Drs. David Soergel, SVP Clinical Development, Franck Skobieranda, VP Clinical Development, Michael Lark, CSO and Mr. Bob Prachar, SVP Commercial and Corporate Strategy will be attending the American Pain Society 33rd Annual Scientific Meeting from Wednesday April 30 to Saturday May 2, 2014 in Tampa Florida. Dr. Soergel will be presenting a poster entitled “TRV130, a novel biased opioid ligand, elicits increased analgesia with reduced adverse effects compared to morphine in healthy volunteers” on the morning of Friday May 1st, between 8:30 AM and 10:30 AM.
Copyright © Trevena, Inc.